ArticleJournal of nanobiotechnology2026
ROS-responsive microneedle patch delivering NMN@Cu/CeO₂ nanozyme for restoring immune microenvironment and mitochondrial homeostasis to potentiate diabetic wound healing.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Functionalized bio-patches for intra-abdominal applications.iScience · 2026Review
- Microneedle-based platforms for wound healing: recent advances.Journal of materials chemistry. B · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chronic oxidative stress, mitochondrial dysfunction, impaired Nicotinamide adenine dinucleotide (NAD⁺) biosynthesis, and angiogenesis inhibition are key factors contributing to delayed diabetic wound healing. Restoring mitochondrial homeostasis through NAD⁺ replenishment and reactive oxygen species (ROS) elimination shows therapeutic potential, yet its effective translation requires multifunctional dressings that combine NAD⁺ supplementation, ROS-responsive antibacterial activity, and localized therapeutic agent delivery to advance diabetic wound healing. Herein, we developed a nanozyme-integrated ROS-responsive microneedle patch (NMN@Cu/CeO₂-MN) for co-delivering nicotinamide mononucleotide (NMN) and Cerium oxide copper nanozymes (Cu/CeO₂). NMN was electrostatically loaded into PEI-functionalized nanozymes to enhance NAD⁺ biosynthesis. The patch was constructed with a methacryloylated gelatin (GelMA)-based needle tip embedded with composite nanozymes and a polyvinyl alcohol/phenylboronic acid-modified poly-L-lysine (PVA/EPL-PBA) antibacterial needle base. This design enables sustained and localized delivery while providing robust antibacterial and pro-regenerative properties. NMN@Cu/CeO₂-MN promoted endothelial cell proliferation, migration, tube formation, and mitochondrial homeostasis by scavenging intracellular ROS and restoring NAD⁺ metabolism. In diabetic mice, the patch significantly enhanced M2 macrophage polarization, alleviated inflammation, and accelerated wound healing through activation of the SIRT1/Nrf2/HO-1 signaling pathway, accompanied by enhanced angiogenesis and collagen deposition. These findings suggest that NMN@Cu/CeO₂-MN represents a potent therapeutic strategy targeting mitochondrial dysfunction and metabolic imbalance in diabetic wound repair.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.